Brittany Lovely

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.

The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.

Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.

Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.

The complete response or complete response with incomplete bone marrow recovery rate was 61% for patients with chronic lymphocytic leukemia and high-risk disease.

The PARP inhibitor talazoparib has been approved in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.

Appropriate monitoring of infusion-related reactions requires up-to-date knowledge of the latest criteria for adverse event management, health system policies, and protocols for reporting.

Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.

The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer

The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.

Acknowledging and addressing maladaptive coping mechanisms may help reduce moral distress and burnout among oncology nurses.

Elizabeth R. Cullen, MSN, ARNP, highlights the efficacy of avasopasem manganese in mitigating severe oral mucositis in patients with locally advanced head and neck cancer.

Julie C. Martin DNP, AOCN, FNP-BC, discusses best practices to approaching conversations on clinically actionable genomic results with patients.

Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

The antibody-drug conjugate trastuzumab deruxtecan has demonstrated clinical activity among patients with uterine carcinosarcomas, regardless of HER2 expression level.

The FDA has granted full approval to pembrolizumab (Keytruda) for certain adult and pediatric patients with advanced MSI-H or dMMR solid tumors.

FDA has approved the BRAF/MEK combination of dabrafenib plus trametinib for pediatric BRAF V600E–mutant low-grade glioma. The label comes with a warning for pyrexia.

The median overall survival was 42.1 months with abiraterone plus olaparib and 34.7 months with abiraterone plus placebo in patients with metastatic castration-resistant prostate cancer.

Frontline ponatinib plus reduced-intensity chemotherapy yielded a higher minimal residual disease-negative complete remission rate than imatinib in the phase 3 PhALLCON study.

Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.

The FDA has granted an accelerated approval to elacestrant (Orserdu) for the treatment of patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer following at least 1 prior lines of endocrine therapy.

Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IB, II, or IIIA following resection and platinum-based chemotherapy.

The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.

Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.

A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.

During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.

After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.